Lab‑on‑a‑chip growth

A lab-on-a-chip is a tiny device that moves droplets through hair-thin channels to run tests that once needed a full bench, and analysts now expect that market to reach $11.45 billion by 2030 from about $6.6 billion in 2024. (grandviewresearch.com) Grand View Research put the 2024 market at $6,614.1 million and forecast 9.8% annual growth through 2030. Its March 2025 report said reagents and consumables are a major product category, alongside instruments and software. (grandviewresearch.com) Most of that hardware depends on microfluidics, which pushes very small liquid volumes through miniature channels etched or molded into plastic, glass, or silicon. A 2021 review in *Micromachines* said the field’s core manufacturing choices include molding, lamination, and 3D printing, each with tradeoffs in cost, precision, and scale. (pmc.ncbi.nlm.nih.gov) The Food and Drug Administration has also been seeing more of these devices. The agency said medical-device submissions using microfluidics rose by more than 400% from 2013 to 2018, measured with a three-year moving average. (fda.gov) That rise has pushed attention toward validation, the step where companies prove a chip works the same way every time. The Food and Drug Administration’s microfluidics program has focused on issues including leakage, bubble formation, cracks, and channel obstructions that can cause device failure. (fda.gov) Researchers at the National Institute of Standards and Technology said leakage testing is routine for microfluidic devices because channels are often smaller than 1 millimeter and small defects can disrupt flow. A 2022 review in *Micromachines* said the field still needs more standardization around leakage testing as devices move toward wider use. (tsapps.nist.gov, pmc.ncbi.nlm.nih.gov) Those checks spill into the supply chain because many chips use custom plastics, adhesives, membranes, coatings, and molded cartridges that cannot be swapped casually after validation. A 2022 perspective in *Biomicrofluidics* said one of the main gaps in commercialization is the jump from lab prototypes to industrial-scale production. (pubs.aip.org) Regulators require that purchased parts and services meet defined specifications. In the U.S., 21 CFR 820.50 says device manufacturers must establish procedures for evaluating suppliers and contractors and describe the quality requirements those suppliers must meet. (law.cornell.edu) That requirement now sits inside a newer rulebook. The Food and Drug Administration said its Quality Management System Regulation took effect on February 2, 2026, updating 21 CFR Part 820 and incorporating ISO 13485:2016, the international medical-device quality standard, by reference. (fda.gov) For buyers of microfluidic consumables, the result is a market that is getting bigger at the same time its parts need tighter documentation, repeatable manufacturing, and more supplier oversight. The chips are shrinking the lab, but the work behind qualifying every channel, seal, and cartridge is getting larger. (grandviewresearch.com, fda.gov)